Literature DB >> 12722324

[Prognostic significance of serum uric acid in patients with chronic obstructive pulmonary disease receiving home oxygen therapy].

Nagato Sato1, Kazuyoshi Kurashima, Mikio Ubukata, Noboru Takayanagi, Hidekazu Matsushima, Tsutomu Yanagisawa, Daido Tokunaga, Yutaka Sugita, Minoru Kanazawa.   

Abstract

Home oxygen therapy (HOT) not only prolongs life expectancy but also improves quality of life. Serum uric acid (UA), the final product of purine catabolism, has been shown to be increased in the hypoxic state. To elucidate the prognostic significance of serum UA in patients with chronic obstructive pulmonary disease (COPD) receiving HOT, we assessed the ratio between the serum concentration of UA and creatinine (Cr) in 91 outpatients with COPD. During a mean follow-up period of 31 months, 24 patients died of acute exacerbation of COPD. The delta UA/Cr ratio was calculated as the percent changes in serum UA/Cr during HOT. delta UA/Cr was increased in non-survivors, but not in survivors, and was negatively correlated with the nadir of oxyhemoglobin saturation (r = -0.32, p < 0.01). Of the clinical and laboratory variables, only the delta UA/Cr ratio was found to be independently related to mortality by a multivariate Cox proportional-hazards analysis. The Kaplan-Meier survival curves divided into values below and above the median value (9.7%) of this ratio demonstrated that mortality was significantly higher among patients with high values than among those with low values (log-rank test: p < 0.05). We conclude that the delta UA/Cr ratio appears to be a reliable marker of prognosis, and may be useful for the long-term follow-up of outpatients with COPD receiving HOT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12722324

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  7 in total

1.  Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease.

Authors:  Eduardo Garcia-Pachon; Isabel Padilla-Navas; Conrado Shum
Journal:  Lung       Date:  2007-02-09       Impact factor: 2.584

2.  The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study.

Authors:  Yasuko Aida; Yoko Shibata; Daisuke Osaka; Shuichi Abe; Sumito Inoue; Koji Fukuzaki; Yoshikane Tokairin; Akira Igarashi; Keiko Yamauchi; Takako Nemoto; Keiko Nunomiya; Hiroyuki Kishi; Masamichi Sato; Tetsu Watanabe; Tsuneo Konta; Sumio Kawata; Takeo Kato; Isao Kubota
Journal:  Int J Med Sci       Date:  2011-08-05       Impact factor: 3.738

3.  Serum Uric Acid Levels and Uric Acid/Creatinine Ratios in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients: Are These Parameters Efficient Predictors of Patients at Risk for Exacerbation and/or Severity of Disease?

Authors:  Nagihan Durmus Kocak; Gulsah Sasak; Ulku Aka Akturk; Metin Akgun; Sibel Boga; Aysun Sengul; Sinem Gungor; Sibel Arinc
Journal:  Med Sci Monit       Date:  2016-11-03

4.  Predictive value of serum uric acid in hospitalized adolescents and adults with acute asthma.

Authors:  Nasser Keshar Abdulnaby; Ashraf Othman Sayed; Nehad Mohamed Shalaby
Journal:  Ther Clin Risk Manag       Date:  2016-11-14       Impact factor: 2.423

5.  The association between risk of airflow limitation and serum uric acid measured at medical health check-ups.

Authors:  Atsuro Fukuhara; Junpei Saito; Suguru Sato; Kazue Saito; Naoko Fukuhara; Yoshinori Tanino; Xintao Wang; Katsuaki Rinno; Hitoshi Suzuki; Mitsuru Munakata
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-04-19

6.  Serum Uric Acid in Chronic Obstructive Pulmonary Disease: A Hospital Based Case Control Study.

Authors:  Rajlaxmi Sarangi; Nirupama Varadhan; Jyotirmayee Bahinipati; Asha Dhinakaran; Kandasamy Ravichandran
Journal:  J Clin Diagn Res       Date:  2017-09-01

7.  Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease.

Authors:  Xin Zhang; Lijie Liu; Rui Liang; Shoude Jin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.